IXHL News and Press, Incannex Healthcare Limited From 10/11/22

MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic me...

MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet med...

Highlights: Highly experienced pharmaceutical executive with 20+ years at Pfizer and 10+ years at Novo Nordisk Secured FDA registration and marketing approval for 12 significant new drugs in the past 10 years at Novo Nordisk in his capacity of Vice President – US Regu...

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A PR Newswire Highlights: Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A Engagement of Curia follows achievement of "proof-of-concept" formulation development ...

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement PR Newswire MELBOURNE, Australia , July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ...

Incannex Healthcare ( NASDAQ: IXHL ) is trading 9.3% higher after the company said it had received approval from Australia's Bellberry Human Research Ethics Committee for a phase 1 trial testing its anti-inflammatory drug IHL-675A. The company's drug is a comb...

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A PR Newswire Highlights: Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of ...

Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference PR Newswire MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL ), ('Incannex' or the 'Company') a clinical-stage ph...

Australia-based developer of medicinal cannabinoids Incannex Healthcare (NASDAQ:IXHL) has added ~20% in the pre-market Friday after the company announced favorable results from a Phase 2 proof-of-concept clinical trial for IHL-42X, an experimental drug for obstructive sleep apnoea. ...

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea PR Newswire Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses ...